Form 4: Revolution Medicines' Chief Operating Officer, Margaret Horn, Reports Acquisition of Shares and Stock Options

Margaret Horn, Chief Operating Officer of Revolution Medicines, reports acquiring 28,600 shares of common stock and 100,100 stock options on March 1, 2025.

Summary

• This Form 4 filing details changes in beneficial ownership for Margaret Horn, the Chief Operating Officer of Revolution Medicines, Inc.
• On March 1, 2025, Ms. Horn acquired 28,600 shares of common stock.
• These shares were acquired at a price of $0.
• Following this transaction, Ms. Horn beneficially owns 156,591 shares of common stock, including 97,476 restricted stock units.
• Ms. Horn also acquired 100,100 stock options with an exercise price of $40.74 on the same date.
• These options vest monthly from March 1, 2025, over four years, subject to continued service.
• The options expire on February 28, 2035.
• After the transaction, Ms. Horn directly owns 100,100 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and options by the COO suggests confidence, but it's a routine filing and doesn't provide strong directional information.

Positives

• The acquisition of shares and stock options by the COO could be seen as a positive sign, indicating confidence in the company's future prospects.

Future Outlook

The vesting schedule of the stock options indicates a long-term commitment from the COO, as the options vest over a four-year period contingent on continued service.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's value and future prospects.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the biotechnology industry, used to align management's interests with those of shareholders.
• The vesting schedule of the options is fairly standard, with monthly vesting over four years being a typical arrangement.
• Comparing the size of the grant to those of peer companies would require further analysis of Revolution Medicines' compensation policies and the grants made to executives at comparable firms.

Stakeholder Impact

• Shareholders may view the COO's acquisition of shares and options as a positive signal, potentially increasing investor confidence.
• Employees may see this as a sign of stability and commitment from the leadership team.

Key Dates